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Boston, Massachusetts; and Portland, OregonVenous thromboembolism is common. Most pulmonary emboli arise as thromboses in the deep veins of the
lower extremities and may result in serious complications. Inferior vena cava ﬁlters (IVCF) are intended to
prevent the passage of deep vein thrombosis to the pulmonary arteries. Accepted indications for IVCF
placement include the presence of acute venous thromboembolism with inability to administer
anticoagulation medication or failure of anticoagulation. Despite these clear indications, IVCF have been
commonly placed in patients for primary prevention of pulmonary emboli in patients deemed to be at high
risk, along with several other “soft” indications. As a result, IVCF use has been rising over the past 2 decades,
especially given the retrievable nature of modern devices. Nonetheless, IVCF are not free of complications,
which may occur during implantation and retrieval and while retained in the body. Despite this increase in
use, the long-term efﬁcacy remains unclear, and the management of patients with retained ﬁlters is often
controversial. Finally, ﬁlter retrieval in eligible patients is relatively infrequent, suggesting that systems
must be in place to improve appropriate ﬁlter use and to increase retrieval. (J Am Coll Cardiol Intv
2013;6:539–47) ª 2013 by the American College of Cardiology FoundationVenous thromboembolism (VTE) is common,
with a reported incidence of 422 of 100,000
people in the United States (1). Left untreated,
pulmonary embolism (PE) will occur in as many
as 40% of all proximal deep vein thrombosis
(DVT) (2). Whereas ﬁrst-line treatment for VTE
is anticoagulation medication, some patients will
experience treatment failure, and anticoagulation
is contraindicated in others. Inferior vena cava
ﬁlters (IVCF), which represent an evolution of
earlier techniques, have been gaining popularity
(3). A review of trends over 21 years in the U.S.
National Discharge Survey (1979 to 1999) and
a Medicare survey citing trends between 1999 and
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February 20, 2013, accepted March 1, 2013.IVCF (4,5). Hospitalization rates for VTE have
risen during the same period, although the rate of
rise has ﬂattened (1,6), especially when compared
with prophylactic (7) and retrievable IVCF
(rIVCF) use (8).Indications for IVCF Implantation
There is signiﬁcant controversy regarding the
appropriate indications for IVCF placement.
Recommendations have been suggested as part of
several professional medical society consensus docu-
ments; however, the body of literature is generally
lacking.There are signiﬁcant differences among these
guidelines (Table 1) (9–13). It is noteworthy that
whereas the Society for Interventional Radiology’s
guidelines delineate more instances in which ﬁlter
deployment may be considered appropriate, the
AmericanCollege of Chest Physicians’ guidelines are
actually less proscriptive, particularly given their rec-
ommendation to consider a subjective assessment of
bleeding risk as a modiﬁer of several indications (9).
Although all published guidelines agree that
IVCF are indicated in patients who have an acute
VTE and who cannot receive anticoagulation
medications or in whom adequate anticoagulation
has clearly failed despite evidence of appropriate
use and effect, some indications are more
Weinberg et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 6 , 2 0 1 3
Inferior Vena Cava Filters J U N E 2 0 1 3 : 5 3 9 – 4 7
540controversial. Retrievable inferior vena cava ﬁlters (rIVCF)
are inserted perioperatively in patients undergoing surgical
pulmonary embolectomy with the intent of reducing the
effect of post-surgical PE in this unstable population (14).
In a retrospective analysis of mortality in 520 patients who
were unstable secondary to PE and who underwent embo-
lectomy, all of whom received an IVCF, mortality was lower
than in 430 patients who did not receive a ﬁlter (25% to
58%, p < 0.0001) (15). Furthermore, IVCF placement in
patients with poor cardiopulmonary reserve is considered a
relative indication by most guidelines (Table 1). The data to
support this, however, are poor (9,16). Another relative
indication for IVCF in several guidelines are free-ﬂoating
iliocaval DVT; however, data are conﬂicting (17,18).
Nevertheless, this subset of DVT still appears in the Society
for Interventional Radiology guidelines and ACR appro-
priateness criteria as a relative indication for an IVCF
(Table 1).
IVCF have been advocated for patients undergoing phar-
macologic and pharmacomechanical thrombolysis of DVTAbbreviations
and Acronyms
CI = conﬁdence interval(s)
DVT = deep vein thrombosis
IVC = inferior vena cava
IVCF = inferior vena cava
ﬁlter(s)
rIVCF = retrievable inferior
vena cava ﬁlter
PE = pulmonary embolism
VTE = venous
thromboembolismdue to the risk of “breakaway”
pulmonary embolization (19). In
a prospective analysis of 174
patients being treated with strep-
tokinase for DVT via a temporary
ﬁlter catheter, emboli were
detected within the ﬁlter in
31.1%, 1 of which was as large as
6.5 cm (20). In an analysis of 17
patients who received rIVCF
prior to treatment with catheter-
directed thrombolysis or phar-
macomechanical thrombolysis for
DVT, a trapped thrombus wasobserved in 8 (47.1%) (19). Conversely, other studies have not
shown a clinical beneﬁt ofﬁlters during thrombolysis. Filter use
and symptomatic PE were very low in a retrospective case-
controlled study of catheter-directed thrombolysis in
303 limbs, where PE occurred in 6 patients (21).
IVCF are advocated for high-risk populations without
VTE as a prophylactic measure, such as in trauma patients.
However, there are several points of controversy regarding
this practice. First, deployment-related complications,
although uncommon and usually mild, can add morbidity
(22). Second, patients will be at risk for long-term
complications related to the device if the ﬁlter is not
removed. Third, the reported incidence of lethal PE in
trauma patients varies widely in the literature. In a review of
16 case series concerning trauma patients, PE occurred in
0% to 10% without a ﬁlter; however, information regarding
patient characteristics and outcomes was limited (23).
Fourth, there are alternatives to IVCF for thrombopro-
phylaxis in many of these patients. In a randomized
controlled trial of 442 trauma patients randomized tointermittent pneumatic compression or low-molecular-
weight heparin, both treatments seemed effective (24).
However, in a meta-analysis pooling data regarding
4,093 subjects in 73 studies that examined reported VTE
incidence in trauma patients, the overall incidence for DVT
and PE were 11.8% and 1.5%, respectively, and were not
shown to be reduced by pharmacological or mechanical
prophylaxis (25). Despite these uncertainties, prophylactic
IVCF are commonly inserted in trauma patients in some
institutions (26–29).
Another patient group that is at high risk for VTE
is patients undergoing spine surgery. Over a 6-month
follow-up period, 129 patients who underwent spine
surgery and received a prophylactic IVCF did not develop
VTE, whereas a matched cohort of 193 patients who
received only mechanical thromboprophylaxis developed
8 PE over the same period (30). However, in another
series in which 74 prophylactic IVCF were inserted,
whereas the median time-to-event was not available,
23 patients developed DVT and 1 developed PE after
11 months (31).
IVCF as an alternative to anticoagulation have been
suggested in patients with brain tumors and VTE. A
retrospective analysis compared survival of 136 patients with
brain cancer or intracranial hemorrhage and VTE who were
treated with an IVCF and 39 patients who received anti-
coagulation treatment (32). In an adjusted model, the study
showed a decrease in in-hospital mortality (8.8% vs. 12.8%)
and an increase in total survival time (21 weeks vs. 11 weeks)
in patients who received ﬁlters; however, both were not
statistically signiﬁcant, possibly due to lack of sufﬁcient
power.
Prophylactic IVCF have been advocated for chronically
immobilized patients, although many of them can safely
receive anticoagulation or be ﬁtted with intermittent pneu-
matic devices. In a retrospective imaging-based report of
a single-center experience of 371 patients with stroke who
received an IVCF, most commonly for contraindications
to anticoagulation (68%) and as prophylaxis (22%), PE
occurred in 54 (15%) within a median of 3 weeks, DVT in
60 (16%), and symptomatic inferior vena cava (IVC)
thrombosis in 5 (1.3%) (33).
Prophylactic IVCF are also being used in patients
undergoing elective open gastric bypass surgery. These
patients have a 1% to 4% chance of PE despite anti-
coagulation, most commonly within 1 month of surgery
(34,35). Nonetheless, the quality of literature to support this
practice is poor. A systematic review of IVCF use in bariatric
surgery identiﬁed 11 studies, none of which were random-
ized. Four studies compared an IVCF to a non-IVCF group
and 7 were case series (36). Most ﬁlters were implanted in
high-risk patients; however, the deﬁnition for high risk
differed between studies and little information was available
regarding ﬁlter retrieval.
Table 1. Societal Guidelines for IVC Use
ACCP (9) SIR (10,12) Appropriateness Criteria (13) AHA (11)*
Primary Therapy for Acute VTE is Pharmacologic
Absolute Indications/Evidence Level I or Level IIa or High Appropriateness
Acute VTE and contraindication to
anticoagulation
VTE and contraindication to anticoagulation Chronic symptomatic PE Adult patients with any conﬁrmed VTE with
contraindications to anticoagulation or
with active bleeding complication
Failure of anticoagulation in patients with
VTE including recurrent VTE, complication
of anticoagulation, and inability to achieve
or maintain therapeutic anticoagulation
Recurrent acute PE despite therapeutic
anticoagulation, it is reasonable to place
an IVC ﬁlter
Relative Indications/Evidence Level IIb or Mid-Level Appropriateness
Unstable patients with PE may beneﬁt from
IVCF in conjunction with anticoagulation
therapy
VTE with limited cardiopulmonary reserve Acute PE and/or iliofemoral
DVT*
Patients with acute PE and very poor
cardiopulmonary reserve, including
those with massive PE
Large, free-ﬂoating proximal DVT Free-ﬂoating iliofemoral DVT
Massive PE treated with thrombolysis/
thrombectomy or chronic PE treated
with thromboendarterectomy
Massive PE treated with thrombolysis/
thrombectomy or chronic PE treated
with thromboendarterectomy
Thrombolysis for iliocaval DVT rIVCF for phlegmasia cerulea
dolens undergoing
endovascular treatment
Iliocaval DVT
Recurrent PE with a ﬁlter in place
Difﬁculty achieving anticoagulation or poor
compliance to anticoagulation treatment
High risk of complications of anticoagulation
(e.g., fall risk)
Prophylaxis for patients with severe trauma,
closed head injury, spinal cord injury,
multiple long bone injuries, prolonged
immobilization
rIVCF as prophylaxis in
high-risk patients
Not Indicated/Not Appropriate
Prophylaxis Calf vein thrombosis and
upper extremity DVT
Routinely as an adjuvant to anticoagulation
and systemic ﬁbrinolysis in the treatment
of acute PE
In addition to anticoagulation for the
treatment of VTE
*The appropriateness criteria are not clear in their scoring of acute VTE and contraindication to anticoagulation.
ACCP ¼ American College of Chest Physicians; AHA ¼ American Heart Association; DVT ¼ deep vein thrombosis; IVC ¼ inferior vena cava; IVCF ¼ inferior vena cava ﬁlter; PE ¼ pulmonary embolism;
rIVCF ¼ retrievable inferior vena cava ﬁlter; SIR ¼ Society of Interventional Radiology; VTE ¼ venous thromboembolism.
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541Filters are occasionally used in high-risk patients in
conjunction with anticoagulation, recognizing the imper-
fection of standard anticoagulant therapy. In a comparison
of outcomes of 251 patients who received both an IVCF and
anticoagulation medications, most commonly for massive
PE or VTE and failure of anticoagulation, and 1,377
patients receiving anticoagulation therapy alone for various
indications, there was no difference in the incidence of PE
at 90 days and 5 years and a nonsigniﬁcant trend toward
more DVT in the IVCF group at 5 years (41.4% vs. 36.2%,
p ¼ 0.12) (37). In the PREPIC (Prévention du Risque
d’Embolie Pulmonaire par Interruption Cave) trial, among
24 patients without a ﬁlter who developed PE, 46% were
receiving anticoagulation medications (38). It is noteworthy
that a Cochrane review of combined intermittent compres-
sion and anticoagulation for VTE prevention in high-riskpatients showed the combination to be effective and
safe (39).
Cancer patients being treated with anticoagulation for
VTE are at particularly increased risk for recurrent VTE and
bleeding (40). Consequently, IVCF are often indicated in
this patient population in the setting of VTE. Mortality is
increased in patients with malignancy regardless of IVCF
use (41). Another concern in the cancer patient receiving an
IVCF is caval thrombosis. A retrospective analysis of
outcomes of 308 patients with cancer who had IVCF
inserted for various indications reported IVC thrombosis in
14 (4.5%), PE in 4 (1.3%), and retroperitoneal hemorrhage
in 2 (0.7%) (42). Most patients (248 [80.5%]) had either
locally advanced or metastatic cancer. Also, in a multivari-
able analysis of the 8-year follow-up of the PREPIC trial,
cancer was associated with increased risk for recurrent DVT
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542(hazard ratio: 2.46, 95% conﬁdence interval [CI]: 1.27 to
4.73, p ¼ 0.007) (38).
Are IVC Filters Effective?
Do They Prevent Pulmonary Emboli?
A population-based study analyzed hospitalization records
from 1991 to 1995 to ﬁnd that the rate of rehospitalization
for PE did not decrease with the use of IVCF, whereas
rehospitalization for DVT increased (43). Furthermore, the
investigators of a Cochrane database review could not draw
ﬁrm conclusions regarding the effectiveness of PE reduction
with IVCF use (44). There are no studies that randomized
patients to receive either an IVCF or anticoagulation treat-
ment. The PREPIC trial was a prospective, randomized,
controlled study of 400 patients with DVT who were
assessed to be at high risk for PE to receive anticoagulation
medications with or without 1 of 3 types of permanent
IVCF: VenaTech LGM (B. Braun, Woburn, Massachu-
setts), titanium Greenﬁeld (Boston Scientiﬁc, Natick,
Massachusetts), or Bird’s Nest (Cook Medical, Bloo-
mington, Indiana) (45). Patients were actively screened for
PE at baseline and after 8 to 12 days, but DVT was deﬁned
only with associated symptoms. At 12 days, there was
a signiﬁcant reduction in PE in the IVCF group (4.8% vs.
1.1%, p ¼ 0.03). Many patients died of causes unrelated to
VTE, and IVCF did not show a mortality beneﬁt. By
2 years, more patients in the ﬁlter group developed a symp-
tomatic DVT (20.8% vs. 11.6%, p ¼ 0.02) and mortality
remained similar between groups (21.6% vs. 20.1%, p ¼
0.65). Furthermore, only a nonsigniﬁcant decrease in PE in
the IVCF group was noted (3.4% vs. 6.3%, p ¼ 0.16). At
8 years of follow-up, there was still no mortality beneﬁt,
despite a persistent signiﬁcant reduction in PE, and DVT
rate was still increased in the IVCF group (38). Unstable
patients with PE have the greatest potential to appreciate
a mortality beneﬁt from IVCF. A retrospective analysis of
outcomes in 38,000 patients who were unstable as a result of
PE revealed a 35% mortality beneﬁt for patients who had an
IVCF in place compared with those who did not (33% vs.
51%, respectively, p < 0.001) (46).
Some studies actually showed worse outcomes for patients
who received an IVCF. A retrospective, population-based
study examined the outcomes of 1,547 patients, 203 of
whom had a permanent IVCF placed for various indications.
At a median of 926 days, all-cause mortality was higher in
the ﬁlter group (p < 0.001) and more patients in this group
had DVT (21% vs. 14.9%, p ¼ 0.009), whereas the inci-
dence of PE was no different (1.7% vs. 5.3%, p ¼ 0.18) (47).
Nonetheless, patients who received ﬁlters were more likely to
be more severely ill than were those who did not.
A direct comparison of efﬁcacy and complications
between permanent IVCF and rIVCF is complicated as
these are 2 heterogeneous groups of devices. However, aretrospective series comparing 427 rIVCF and 275 perma-
nent IVCF over a mean of 11.4 months reported PE, DVT,
and IVC thrombosis rates to be similar (4% vs. 4.7%,
p ¼ 0.67; 11.3% vs. 12.6%, p ¼ 0.59; and 1.1% vs. 0.5%,
p ¼ 0.39, respectively) (48). Patients with permanent IVCF
were older and more likely to have an intercurrent malig-
nancy; however, rIVCF were inserted more often in patients
with proximal DVT and in patients undergoing catheter-
directed thrombolysis. Similarly, a systematic review of
9,659 permanent IVCF and 860 rIVCF reported PE in
1.1% to 3.2% and DVT in 11.4% of the cohort (49).
Technical Aspects of
IVCF Placement and Removal
Placement of an IVCF should be preceded by an assessment
of the patient’s duration of risk of PE and life expectancy.
Currently, a choice should be made between permanent and
retrievable IVCF (Table 2) (50–52). In the future, these
patients will also be candidates for convertible devices (53).
Prior to the insertion procedure, any available cross-
sectional imaging should be reviewed for IVC and access site
anatomy, patency, and anomalies. The majority of ﬁlters are
placed using ﬂuoroscopic guidance in interventional suites,
but intravascular ultrasound can be used for bedside place-
ment in unstable patients or immovable patients (54)
(Fig. 1). Depending upon the design of the ﬁlter and
diameter of the delivery sheath, ﬁlters can be inserted from
the femoral, jugular, or antecubital veins. The IVC is imaged
to assess diameter, patency, presence of congenital anoma-
lies, and the location of the renal veins (Fig. 2A). The usual
target-landing zone for IVCF is the infrarenal IVC, close to
the level of the renal veins (Fig. 2B). The diameter of the
IVC in the target-landing zone is important, as each ﬁlter is
rated for a maximum IVC diameter, above which the like-
lihood of embolization of the ﬁlter itself is increased
(Table 2). The maximum IVC diameter that can be treated
is 40 mm (Bird’s Nest ﬁlter), with most devices intended for
cavae up to 28 to 31 mm in diameter. Some devices require
minimum caval diameters in order to open or ﬁxate properly.
This information is provided in each device’s instructions
for use. In patients with certain IVC anomalies, pregnancy
(or likelihood of future pregnancy), extensive IVC thrombus,
or renal vein thrombosis, the ﬁlter can be placed in the
suprarenal IVC (55). Outcomes of ﬁlters in this location
appear to be similar to those placed in the infrarenal IVC.
The ﬁlter is then inserted according to the instructions for
use. Conﬁrmation of complete IVCF deployment, place-
ment in the intended location, and correct orientation are
important. Operator errors include misplacement of the
ﬁlter in nontarget veins such as renal, gonadal, and
ascending lumbar. Many ﬁlters are packaged in universal
delivery sets, so that there is potential for the device to be
inadvertently placed upside down.
Table 2. FDA Approved rIVCF Main Characteristics
Filter Recommended Time-to-Retrieval
Introducer
Size Comments
Celect (Cook Medical,
Bloomington, Indiana)
Retrieval was 97% at 179 days and reported
up to 466 days (50)
7-F Can be used up to a maximal IVC size of 30 mm
Gunther Tulip (Cook Medical,
Bloomington, Indiana)
Retrieval success rate was 94% at 12 weeks
and reported up to 494 days (51)
11-F Can be used up to a maximal IVC size of 30 mm
G2 (Bard Peripheral Vascular,
Tempe, Arizona)
Retrieval was 86.9% at 131 days and reported
up to 602 days (52)
7-F Can be used up to a maximal IVC size of 28 mm. High rates of
tilting that precludes retrieval, fracture, and migration have
been reported
Optease (Cordis, Miami Lakes, Florida) 23 days Can be used up to a maximal IVC size of 30 mm
ALN Filter (ALN Implants Chirurgicaux,
Ghisonaccia, France)
“Unlimited” 6-F Approved for IVC up to 28 mm in the United States and
32 mm in Europe
SafeFlo (Rafael Medical Technologies,
Caesarea, Israel)
N/A 6-F Available for IVC 16–25 mm
Option (Rex Medical, distributed by
Argon Medical Devices, Plano, Texas)
175 days 5-F Can be used up to a maximal IVC size of 32 mm
Crux (Crux Biomedical,
Menlo Park, California)
In a multinational study, 98% of ﬁlters were
retrieved within 84  57 days
6-F Can be retrieved from the jugular or the femoral approach.
Two sizes offer protection for IVC sizes 17–28 mm
FDA ¼ U.S. Food and Drug Administration; N/A ¼ not available; other abbreviations as in Table 1.
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543Filter removal is performed with local anesthesia and
intravenous sedation in most cases. Patients on therapeutic
anticoagulation should be maintained in the therapeutic
anticoagulant range at the time of the procedure (56). The
presence of trapped thrombus is excluded with caval
venography. When a large or fresh-appearing thrombus is
found, the procedure is terminated, and the patient main-
tained on anticoagulation medications. In most cases, the
thrombus will resolve in 4 weeks and the ﬁlter will subse-
quently be removed (57).
Each IVCF is designed for removal from a venous-
speciﬁc access: in most cases, the jugular vein. A few devices
can be removed from the femoral venous approach. The
procedure requires ﬂuoroscopic imaging, either single or
bi-plane. After the vena cavogram is performed, a sheath
capable of receiving the ﬁlter is positioned close to theFigure 1. IVUS-Guided IVC Filter Insertion
(A) Axial intravascular ultrasound (IVUS) image showing the top of the ﬁlter (long a
(B) IVUS image with the deployed Optease ﬁlter (Cordis Corp., Miami Lakes, Florida)device. A variety of devices and techniques with escalating
aggressiveness can be used to remove a ﬁlter. When ﬁlters
are centered in the IVC and not ﬁrmly attached to the walls
of the cava, simple snares or dedicated ﬁlter-grasping devices
are often effective. In some cases, the ﬁlter is not easily
engaged, and shaped catheters are necessary to pass a
guidewire around the ﬁlter. The guidewire tip is then snared
and externalized through the sheath, effectively constructing
an in situ snare (58). After securely engaging the ﬁlter, the
sheath is advanced over the device to collapse it and/or the
device is pulled into the sheath. Common sheath sizes range
from 8- to 12-F. The ﬁlter should be inspected for missing
elements after removal, and a repeat IVC venogram should
be obtained to document integrity and patency of the IVC.
Adherent or tilted ﬁlters may require advanced retrieval
techniques including dissection away from the wall of therrow) at the level of the renal veins (short arrows) prior to deployment.
showing full expansion of the device. IVC ¼ inferior vena cava.
Figure 2. IVCF Insertion Venogram
(A) Normal venogram of the inferior vena cava. (B) Venogram showing an inferior vena cava ﬁlter (IVCF) placed below the renal arteries.
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544IVC with endobronchial forceps or laser-rimmed lead
extraction sheaths (59). In extreme cases, open surgical
removal can be performed. Whenever advanced techniques
are required, the risk of a complication is increased, and
leaving the ﬁlter in place permanently should be considered
as an important option.Complications Associated With IVCF
Most of the IVCF complication-related literature is
composed of case reports. It is likely that the complication
rate is under-reported (60). The MAUDE (Manufacturer
and User Facility Device Experience) database, a Food and
Drug Administration voluntary registry, has accumulated
only 842 IVCF-related complications in 10 years between
2000 and 2010 (61). In this database, most complications
were reported 30 days or later after implantation. Different
ﬁlters seem to vary in their complication proﬁle, but
comparisons are scarce. Complications may occur during
implantation or retrieval or when a ﬁlter is retained. Inser-
tion-related complications have been reported in 4% to 15%
of patients and include puncture site–related problems,
misplacement, migration, ﬁlters failing to deploy properly,
and vena cava perforation (22,62). An uncommon compli-
cation is symptomatic access site DVT (3%); however,
asymptomatic thrombi that can be detected by ultrasound
are of questionable clinical signiﬁcance and much more
common (35%) (63,64). Complications of retained ﬁlters
and their reported incidence, when available, include ﬁlter
migration or embolization (3% to 69%), strut fracture and
penetration (9% to 24%), IVC thrombosis (6% to 30%),
lower extremity edema, post-thrombotic syndrome (5% to
70%), DVT (0% to 20%) (23), and recurrent PE (3% to 7%)
(4,16,48,62) (Fig. 3). It is noteworthy that retained
thrombus within the ﬁlter is often cited as proof of ﬁlter
effectiveness, and, indeed, some breakthrough PE are fatal.
Also of note is that IVC thrombosis can sometimes beasymptomatic, such as when discovered on imaging per-
formed for other indications (65).
Management of Patients With IVCF
It is believed that many of the thrombotic complications of
IVC ﬁlters can be avoided by prompt removal of rIVCF. As
time from implantation elapses, the chances for VTE persist
(38), but contraindications to anticoagulation may have
resolved (66). Furthermore, most available data points to the
fact that as ﬁlters are retained, more long-term complica-
tions may occur (38,66). In a series of 140 rIVCF inserted in
trauma patients, complications occurred in 13.3% despite
a median dwell time of only 21 days (67). Accordingly,
guidelines suggest that rIVCF should be retrieved (9,11) and
the U.S. Food and Drug Administration issued a statement
to this effect (68). Manufacturers typically state that retrieval
is more likely to be successful if attempted within several
weeks to months (69). In most reported series, upward
of 85% of rIVCF could theoretically be retrieved (62).
However, the aforementioned reviews of rIVCF use re-
ported retrieval in only 33.6% and 34% of over 10,000 cases
(60,70). The most commonly cited reasons for nonretrieval
include patient loss to follow-up (28) and lack of follow-up
(71), as well as patient noncompliance (72). In response to
this data, various systems have been devised to improve the
rIVCF retrieval rate. Another still-experimental approach is
to develop absorbable IVCF that will disappear from the
body, preferably after the acute indication has passed (73).
Duration of anticoagulation administration is another
ﬁlter-related management issue. Patients with VTE should
be treated with anticoagulation medication according to
their underlying condition, as retained IVCF are not
speciﬁc indications for anticoagulation therapy (9). If an
IVCF has been deployed because of a contraindication
to anticoagulation, treatment should resume once the
contraindication has subsided (11). Prolonging anti-
coagulation administration in patients with retained ﬁlters
Figure 3. Fractured Bard G2 IVCF
(A) Extracted Bard G2 IVCF with a broken strut and a missing strut. (B) Fluoroscopy showing a retained strut from the Bard G2 IVCF. Abbreviations as in
Figures 1 and 2.
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545has potential advantages such as reducing ﬁlter-related IVC
thrombosis and minimizing recurrent PE, but it also carries
an increased risk of bleeding (74). The presence of an IVCF
as an indication for anticoagulation is still a matter of debate
suffering from a paucity of high-quality data. Most reports
of IVCF-related thrombotic complications lack information
about whether patients were receiving anticoagulation
medications and about the quality and intensity of anti-
coagulation treatment (37). A nonrandomized prospective
cohort of 121 patients with permanent IVCF who were
given long-term anticoagulation treatment reported 6 (5%)
recurrent PE and 24 (19.8%) new DVT during a median
follow-up of 3.1 years, which corresponded to an incident
rate for PE of 1.6 per 100 patient-years (95% CI: 0.7 to 3.5)
and for DVT of 7.0 per 100 patient-years (95% CI: 4.8 to
10.0) (74). IVCF thrombosis that was not clinically evident
was detected by routine ultrasonography in 7 (5.8%)
patients. These were all resolved within 8 weeks of oral
anticoagulation being substituted by low-molecular-weight
heparin. Major bleeding occurred in 8 (6.6%) patients.
Future Issues
As stated throughout this review, several publications in the
ﬁeld of IVCF are of suboptimal quality. Accordingly,
a committee within the Society for Interventional Radiology
convened in 2009 recommended a randomized trial of IVCF
prophylaxis and a comparison between IVCF andanticoagulation therapy in patients who have an indication for
anticoagulation (53). Furthermore, a national IVCF registry
has been developed to collect data regarding patients with
IVCF for 48 months (NCT01367184). Also, a second ver-
sion of the PREPIC trial (PREPIC 2), a multicenter ran-
domized study comparing outcomes of patients with VTE
being treated with anticoagulation therapy with or without
rIVCF, has completed recruitment (NCT00457158).
Conclusions
The increased use of IVCF is not supported by high-quality
evidence. The only indications for IVCF that are widely
accepted are in patients with acute VTE and absolute
contraindications to anticoagulation or in patients who have
failed adequate anticoagulation. Notwithstanding, IVCF
likely have a role in the treatment of some high-risk patient
populations. Further research is needed to ascertain specif-
ically, which patient populations outside these strict criteria
actually beneﬁt from ﬁlter implantation. Finally, prompt
ﬁlter retrieval is crucial as complications may accrue soon
after implantation, and dedicated surveillance must be in
place in centers that perform IVCF implantation.
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